hydroxyurea has been researched along with Apoplexy in 134 studies
Excerpt | Relevance | Reference |
---|---|---|
"We tested the hypothesis that fixed oral moderate-dose hydroxyurea (20 mg/kg per day) for initial treatment of secondary stroke prevention results in an 80% relative risk reduction of stroke or death when compared with fixed oral low-dose hydroxyurea (10 mg/kg per day) in a phase 3 double-blind, parallel-group, randomized controlled trial in children with sickle cell anemia (SCA) living in Nigeria." | 9.69 | Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial. ( Abba, MS; Abdullahi, SU; Aliyu, MH; Ciobanu, M; Covert Greene, BV; DeBaun, MR; Gambo, A; Gambo, S; Hussaini, N; Inuwa, HA; Jordan, LC; Kassim, AA; Musa, B; Rodeghier, M; Sani, S; Sunusi, S, 2023) |
" SPHERE will prospectively determine the benefits of hydroxyurea at MTD for primary stroke prevention, anticipating expanded access to hydroxyurea treatment across Tanzania." | 9.69 | Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa. ( Adams, J; Ambrose, EE; Balyorugulu, G; Charles, M; Howard, TA; Komba, P; Lane, A; Latham, TS; Makubi, AN; McElhinney, KE; Nakafeero, M; O'Hara, SM; Odame, J; Shabani, I; Smart, LR; Songoro, P; Stuber, SE; Ware, RE, 2023) |
" In the low-dose hydroxyurea group, three (3%) of 109 participants had strokes, with an incidence rate of 1·19 per 100 person-years and in the moderate-dose hydroxyurea group five (5%) of 111 had strokes with an incidence rate of 1·92 per 100 person-years (incidence rate ratio 0·62 [95% CI 0·10-3·20], p=0·77)." | 9.51 | Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial. ( Abdullahi, SU; Aliyu, MH; Bello-Manga, H; Borodo, A; DeBaun, MR; Galadanci, A; Galadanci, N; Gambo, S; Ghafuri, DL; Greene, BC; Haliru, L; Hikima, MS; Ibrahim, J; Idris, N; Inuwa, H; Jibir, BW; Jordan, LC; Kassim, A; Kirkham, FJ; Neville, K; Rodeghier, M; Slaughter, JC; Suleiman, A; Tabari, AM; Tijjani, AG; Trevathan, E, 2022) |
"Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) is an NHLBI-sponsored Phase III multicenter randomized controlled clinical trial for children with SCA, stroke, and iron overload (NCT00122980)." | 9.15 | Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. ( Alvarez, O; Helms, RW; Hilliard, L; Iyer, RV; Miller, ST; Mortier, NA; Rogers, ZR; Schultz, WH; Scott, JP; Waclawiw, M; Ware, RE; Yovetich, N, 2011) |
"In the past two decades, two landmark randomized controlled trials (RCT) have been completed among individuals with sickle cell disease (SCD), the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial." | 9.12 | Limitations of clinical trials in sickle cell disease: a case study of the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial. ( Debaun, MR; Field, JJ, 2007) |
"Our findings suggest that hydroxyurea is safe and may prevent silent stroke and stroke in sickle cell disease." | 9.01 | The role of hydroxyurea to prevent silent stroke in sickle cell disease: Systematic review and meta-analysis. ( Hasson, C; Mhaskar, R; Rico, J; Veling, L, 2019) |
"We demonstrated changes in SCD care utilization over time, including increased hydroxyurea use, changes in transfusion rates, and increased attention to iron overload management." | 8.31 | Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019. ( Lai, KW; Lane, PA; Maillis, AN; Snyder, AB; Tang, AY; Zhou, M, 2023) |
"We undertook a cost effectiveness analysis (CEA) of hydroxyurea (HU) in preventing stroke recurrence and/or death." | 7.81 | Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis. ( Abdulkadri, A; Bortolusso Ali, S; Cunningham-Myrie, C; King, LG; Knight-Madden, J; Reid, M; Waugh, A, 2015) |
" Hydroxyurea is a standard therapy in patients with history of acute chest syndrome and severe, recurrent, SCD-associated pain episodes, but has not been established for use with other sickle-associated morbidities." | 7.80 | Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers. ( Jones, GL; Kalpatthi, R; Madden, NA; Woods, G, 2014) |
" In this short communication, we describe a woman with sickle cell anemia responsive to hydroxyurea (HU) therapy who had primary stroke due to paradoxical embolization caused by a large atrial septal defect." | 7.80 | Primary stroke in a woman with sickle cell anemia responsive to hydroxyurea therapy. ( Ballas, SK; Martinez, U; Savage, M, 2014) |
"To compare the outcome after a first clinical stroke, following treatment with and without hydroxyurea (HU)." | 7.79 | Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea. ( Brown, BJ; Lagunju, IA; Sodeinde, OO, 2013) |
" We previously reported the use of hydroxyurea/phlebotomy as an alternative to transfusions to reduce the risk of secondary stroke and improve management of iron overload in 35 children with SCA." | 7.77 | Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. ( Greenway, A; Thornburg, CD; Ware, RE, 2011) |
"For children with SCA and stroke, hydroxyurea effectively prevents secondary stroke and serial phlebotomy leads to complete resolution of transfusional iron overload." | 7.72 | Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. ( Davis, JS; Mortier, NA; Schultz, WH; Sylvestre, PB; Treem, WR; Ware, RE; Zimmerman, SA, 2004) |
" A possible alternative, the prophylactic use of hydroxyurea (HU), has not been tried to determine whether it may prevent recurrent stroke." | 7.71 | Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). ( de Bisotti, R; Fairbanks, V; Sumoza, A; Sumoza, D, 2002) |
"Hydroxyurea is an alternative treatment to decrease stroke risk." | 7.30 | Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. ( Ambrose, EE; Charles, M; Lane, AC; Latham, TS; Makubi, AN; Smart, LR; Songoro, P; Stuber, SE; Ware, RE, 2023) |
" The Fisher's Exact test was used to compare the frequency of subjects who experienced at least one SCA-related adverse event (AE) or serious adverse event (SAE) in each arm and to compare event rates." | 6.78 | Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. ( Alvarez, O; Aygun, B; Bonner, M; Flanagan, J; Lockhart, A; Miller, ST; Mueller, BU; Owen, W; Schultz, W; Scott, JP; Ware, RE; Yovetich, NA, 2013) |
"Stroke is a devastating complication of sickle cell anemia (SCA) with high recurrence if untreated." | 6.77 | Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). ( Helms, RW; Ware, RE, 2012) |
"Ischemic stroke is characterized by high morbidity, disability, and mortality." | 5.91 | Enhanced brain delivery of hypoxia-sensitive liposomes by hydroxyurea for rescue therapy of hyperacute ischemic stroke. ( Hong, Y; Hu, F; Jin, X; Ke, J; Li, S; Shang, X; Wang, K; Wen, L; Wu, X; Xu, Y; Yuan, H; Zhou, W, 2023) |
" SPHERE will prospectively determine the benefits of hydroxyurea at MTD for primary stroke prevention, anticipating expanded access to hydroxyurea treatment across Tanzania." | 5.69 | Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa. ( Adams, J; Ambrose, EE; Balyorugulu, G; Charles, M; Howard, TA; Komba, P; Lane, A; Latham, TS; Makubi, AN; McElhinney, KE; Nakafeero, M; O'Hara, SM; Odame, J; Shabani, I; Smart, LR; Songoro, P; Stuber, SE; Ware, RE, 2023) |
"We tested the hypothesis that fixed oral moderate-dose hydroxyurea (20 mg/kg per day) for initial treatment of secondary stroke prevention results in an 80% relative risk reduction of stroke or death when compared with fixed oral low-dose hydroxyurea (10 mg/kg per day) in a phase 3 double-blind, parallel-group, randomized controlled trial in children with sickle cell anemia (SCA) living in Nigeria." | 5.69 | Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial. ( Abba, MS; Abdullahi, SU; Aliyu, MH; Ciobanu, M; Covert Greene, BV; DeBaun, MR; Gambo, A; Gambo, S; Hussaini, N; Inuwa, HA; Jordan, LC; Kassim, AA; Musa, B; Rodeghier, M; Sani, S; Sunusi, S, 2023) |
" We performed a secondary analysis of participants in the Primary Prevention of Stroke in Children with Sickle Cell Disease in Nigeria trial, a double-blind, parallel-group randomized controlled trial for low-dose or moderate-dose hydroxyurea in children with abnormal transcranial Doppler velocities and a comparison group of participants with nonelevated transcranial Doppler velocities in northern Nigeria." | 5.69 | Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting. ( Abdullahi, SU; Acra, S; DeBaun, MR; Gambo, S; Klein, LJ; Rodeghier, M; Stallings, VA, 2023) |
" In the low-dose hydroxyurea group, three (3%) of 109 participants had strokes, with an incidence rate of 1·19 per 100 person-years and in the moderate-dose hydroxyurea group five (5%) of 111 had strokes with an incidence rate of 1·92 per 100 person-years (incidence rate ratio 0·62 [95% CI 0·10-3·20], p=0·77)." | 5.51 | Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial. ( Abdullahi, SU; Aliyu, MH; Bello-Manga, H; Borodo, A; DeBaun, MR; Galadanci, A; Galadanci, N; Gambo, S; Ghafuri, DL; Greene, BC; Haliru, L; Hikima, MS; Ibrahim, J; Idris, N; Inuwa, H; Jibir, BW; Jordan, LC; Kassim, A; Kirkham, FJ; Neville, K; Rodeghier, M; Slaughter, JC; Suleiman, A; Tabari, AM; Tijjani, AG; Trevathan, E, 2022) |
"Evidence-based practice for stroke prevention in high-income countries involves screening for abnormal transcranial Doppler (TCD) velocity and initiating regular blood transfusions for at least 1 year, followed by treatment with hydroxyurea." | 5.51 | Translating research to usual care of children with sickle cell disease in Northern Nigeria: lessons learned from the SPRING Trial Team. ( Bahago, GY; Bauman, AA; Bello-Manga, H; DeBaun, MR; Farouk, B; Haliru, L; King, AA; Sani, AM; Suleiman, A; Tabari, AM, 2022) |
"Hydroxyurea (HU) has been shown to reduce elevated TCD velocities in children with SCD." | 5.51 | Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea. ( Asinobi, A; Brown, BJ; Esione, A; Ibeh, J; Lagunju, I; Oyinlade, AO; Sodeinde, OO, 2019) |
"Hydroxyurea-induced pneumonitis is unusual." | 5.40 | [Hydroxyurea-induced pneumonia]. ( Claeyssen, V; Decaux, O; Delaval, P; Desrues, B; Girard, A; Jouneau, S; Poullot, E; Ricordel, C, 2014) |
"Hydroxyurea is an antineoplastic agent commonly used to treat essential thrombocytosis." | 5.40 | Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis. ( Gupta, A; Karanth, SS; Prabhu, M, 2014) |
"The standard care protocol requires that children with acute strokes be treated with hydroxyurea at a fixed dose of 20 mg/kg/day within two months of the stroke." | 5.30 | Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial. ( Abdullahi, SU; DeBaun, MR; Galadanci, NA; Jordan, LC; Rodeghier, M, 2019) |
"There is evidence to suggest that hydroxyurea may be effective in decreasing the frequency of pain episodes and other acute complications in adults and children with sickle cell anaemia of HbSS or HbSβºthal genotypes and in preventing life-threatening neurological events in those with sickle cell anaemia at risk of primary stroke by maintaining transcranial Doppler velocities." | 5.22 | Hydroxyurea (hydroxycarbamide) for sickle cell disease. ( Nevitt, SJ; Rankine-Mullings, AE, 2022) |
"Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea (TWiTCH) trial is a randomized, open-label comparison of hydroxycarbamide (also termed hydroxyurea) versus continued chronic transfusion therapy for primary stroke prevention in patients with sickle cell anaemia (SCA) and abnormal TCD." | 5.22 | Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. ( Aygun, B; Cohen, AR; Davis, BR; Fuh, B; Imran, H; Luchtman-Jones, L; Pressel, SL; Schultz, WH; Thompson, AA; Ware, RE; Wood, JC, 2016) |
" We report baseline LIC results from the TWiTCH trial, which compares hydroxyurea with blood transfusion treatment for primary stroke prophylaxis assessed by transcranial Doppler sonography in pediatric SCA patients." | 5.20 | Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. ( Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC, 2015) |
"The Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) trial compared standard (transfusions/chelation) to alternative (hydroxyurea/phlebotomy) treatment to prevent recurrent stroke and manage iron overload in children chronically transfused over 7 years before enrollment." | 5.19 | Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. ( Adams, RJ; Aygun, B; Driscoll, C; Heeney, MM; Helton, KJ; Jackson, SM; Kesler, KL; Krishnamurti, L; Lockhart, A; Miller, ST; Sarnaik, SA; Schultz, WH; Ware, RE, 2014) |
"Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) is an NHLBI-sponsored Phase III multicenter randomized controlled clinical trial for children with SCA, stroke, and iron overload (NCT00122980)." | 5.15 | Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. ( Alvarez, O; Helms, RW; Hilliard, L; Iyer, RV; Miller, ST; Mortier, NA; Rogers, ZR; Schultz, WH; Scott, JP; Waclawiw, M; Ware, RE; Yovetich, N, 2011) |
"In the past two decades, two landmark randomized controlled trials (RCT) have been completed among individuals with sickle cell disease (SCD), the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial." | 5.12 | Limitations of clinical trials in sickle cell disease: a case study of the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial. ( Debaun, MR; Field, JJ, 2007) |
" Current treatment for SCD focuses on primary prevention of complications, such as hydroxyurea for prevention of pain and acute chest syndrome, and chronic transfusion therapy for children who are at high risk for strokes." | 5.12 | Neurologic and Cognitive Outcomes in Sickle Cell Disease from Infancy through Adolescence. ( Fields, ME; Hulbert, ML; Mayer, SL, 2021) |
"Our findings suggest that hydroxyurea is safe and may prevent silent stroke and stroke in sickle cell disease." | 5.01 | The role of hydroxyurea to prevent silent stroke in sickle cell disease: Systematic review and meta-analysis. ( Hasson, C; Mhaskar, R; Rico, J; Veling, L, 2019) |
" The introduction of penicillin prophylaxis, conjugated pneumococcal and Haemophilus influenzae type B vaccines have dramatically decreased the rate of life-threatening infections, while use of hydroxyurea in children has decreased pain and acute chest syndrome events." | 4.90 | The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease. ( DeBaun, MR; Kassim, AA, 2014) |
" The first two trials addressed the use of chronic transfusion to prevent primary stroke; the third utilized the drug hydroxycarbamide (hydroxyurea) and phlebotomy to prevent both recurrent (secondary) stroke and iron overload in patients who had already experienced an initial stroke." | 4.89 | Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. ( Dwan, K; Wang, WC, 2013) |
" Improved understanding of the natural history of complications such as stroke and pulmonary hypertension, effects of treatments, such as hydroxyurea and blood transfusions, as well as the impact of transplantation on organ damage are likely to influence the timing and indication of transplantation." | 4.84 | Hematopoietic cell transplantation: a curative option for sickle cell disease. ( Krishnamurti, L, 2007) |
" prevention of overwhelming bacterial infection, present indications and controversies regarding blood transfusion, prevention of stroke, acute chest syndrome, hydroxyurea therapy--probably the best disease modifying agent at the moment, stem cell transplantation--a cure and certain promising experimental therapies including gene therapy have been discussed in this review." | 4.82 | Advances in management of sickle cell disease. ( Agarwal, MB, 2003) |
"We demonstrated changes in SCD care utilization over time, including increased hydroxyurea use, changes in transfusion rates, and increased attention to iron overload management." | 4.31 | Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019. ( Lai, KW; Lane, PA; Maillis, AN; Snyder, AB; Tang, AY; Zhou, M, 2023) |
" These recommendations include: use of transcranial Doppler ultrasound screening and hydroxyurea for primary stroke prevention in children with hemoglobin SS (HbSS) and hemoglobin Sβ0 (HbSβ0) thalassemia living in low-middle-income settings; surveillance for developmental delay, cognitive impairments, and neurodevelopmental disorders in children; and use of magnetic resonance imaging of the brain without sedation to detect silent cerebral infarcts at least once in early-school-age children and once in adults with HbSS or HbSβ0 thalassemia." | 3.96 | American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. ( Daraz, L; DeBaun, MR; Fox, CK; Jordan, LC; King, AA; Kirkham, FJ; Kraut, MA; McKinstry, RC; Murad, MH; Schatz, J; Telfer, P; Vichinsky, E, 2020) |
"We undertook a cost effectiveness analysis (CEA) of hydroxyurea (HU) in preventing stroke recurrence and/or death." | 3.81 | Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis. ( Abdulkadri, A; Bortolusso Ali, S; Cunningham-Myrie, C; King, LG; Knight-Madden, J; Reid, M; Waugh, A, 2015) |
" Hydroxyurea is a standard therapy in patients with history of acute chest syndrome and severe, recurrent, SCD-associated pain episodes, but has not been established for use with other sickle-associated morbidities." | 3.80 | Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers. ( Jones, GL; Kalpatthi, R; Madden, NA; Woods, G, 2014) |
" He was thought to have had an embolic stroke and was initially treated with warfarin." | 3.80 | Repeated episodes of ischemic stroke over a short period in a patient with essential thrombocythemia on anticoagulant therapy. ( Hirano, T; Isoda, K; Ito, K; Naganuma, M; Nishi, S, 2014) |
" In this short communication, we describe a woman with sickle cell anemia responsive to hydroxyurea (HU) therapy who had primary stroke due to paradoxical embolization caused by a large atrial septal defect." | 3.80 | Primary stroke in a woman with sickle cell anemia responsive to hydroxyurea therapy. ( Ballas, SK; Martinez, U; Savage, M, 2014) |
"To compare the outcome after a first clinical stroke, following treatment with and without hydroxyurea (HU)." | 3.79 | Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea. ( Brown, BJ; Lagunju, IA; Sodeinde, OO, 2013) |
" We previously reported the use of hydroxyurea/phlebotomy as an alternative to transfusions to reduce the risk of secondary stroke and improve management of iron overload in 35 children with SCA." | 3.77 | Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. ( Greenway, A; Thornburg, CD; Ware, RE, 2011) |
"For children with SCA and stroke, hydroxyurea effectively prevents secondary stroke and serial phlebotomy leads to complete resolution of transfusional iron overload." | 3.72 | Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. ( Davis, JS; Mortier, NA; Schultz, WH; Sylvestre, PB; Treem, WR; Ware, RE; Zimmerman, SA, 2004) |
" A possible alternative, the prophylactic use of hydroxyurea (HU), has not been tried to determine whether it may prevent recurrent stroke." | 3.71 | Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). ( de Bisotti, R; Fairbanks, V; Sumoza, A; Sumoza, D, 2002) |
" Optimal zinc dosing and the role of zinc in preventing stroke or death in SCA warrant further investigation." | 3.30 | Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial. ( Bond, C; Conroy, AL; Cusick, SE; Datta, D; Goings, MJ; Jang, JH; John, CC; Krebs, NF; Namazzi, R; Opoka, R; Ryu, MS; Tagoola, A; Tu, W; Ware, RE, 2023) |
"Hydroxyurea is an alternative treatment to decrease stroke risk." | 3.30 | Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. ( Ambrose, EE; Charles, M; Lane, AC; Latham, TS; Makubi, AN; Smart, LR; Songoro, P; Stuber, SE; Ware, RE, 2023) |
"Children with preexisting silent cerebral infarcts receiving blood transfusions had lower hospitalization costs but higher outpatient costs, primarily associated with the oral iron chelator deferasirox." | 3.01 | Economic evaluation of regular transfusions for cerebral infarct recurrence in the Silent Cerebral Infarct Transfusion Trial. ( Cronin, RM; DeBaun, MR; Gay, JC; Hsu, P; Lin, CJ; Rodeghier, M, 2021) |
" The full enrollment to REACH confirms the feasibility of conducting high-quality SCA research in Africa; this study will provide vital information to guide safe and effective dosing of hydroxyurea for children with SCA living in Africa." | 2.87 | Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa. ( Aygun, B; Howard, TA; Kitenge, R; Lane, A; Latham, T; Luís Reis da Fonseca, J; McElhinney, K; McGann, PT; Mochamah, G; Olupot-Olupot, P; Santos, B; Stuber, S; Tomlinson, GA; Tshilolo, L; Wabwire, H; Ware, RE; Williams, TN, 2018) |
"The vast majority of children with sickle cell anemia (SCA) live in Africa, where evidence-based guidelines for primary stroke prevention are lacking." | 2.84 | Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial). ( Ali, S; Aliyu, MH; Amal Galadanci, A; Bello-Manga, H; Belonwu, R; Covert, BV; DeBaun, MR; Galadanci, NA; Jordan, LC; Kassim, AA; Kirkham, FJ; Musa Tabari, A; Neville, K; Phillips, S; Salihu, A; Shyr, Y; Umar Abdullahi, S; Vance, LD; Wudil Jibir, B, 2017) |
"Stroke risk in sickle cell anemia (SCA), predicted by high transcranial Doppler (TCD) velocities, is prevented by transfusions." | 2.82 | Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities. ( Arnaud, C; Bernaudin, F; Biscardi, S; Dalle, JH; Epaud, R; Fourmaux, C; Gluckman, E; Hau, I; Kamdem, A; Kasbi, F; Leveillé, E; Madhi, F; Pondarré, C; Socié, G; Vasile, M; Verlhac, S, 2016) |
" The Fisher's Exact test was used to compare the frequency of subjects who experienced at least one SCA-related adverse event (AE) or serious adverse event (SAE) in each arm and to compare event rates." | 2.78 | Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. ( Alvarez, O; Aygun, B; Bonner, M; Flanagan, J; Lockhart, A; Miller, ST; Mueller, BU; Owen, W; Schultz, W; Scott, JP; Ware, RE; Yovetich, NA, 2013) |
"Stroke is a devastating complication of sickle cell anemia (SCA) with high recurrence if untreated." | 2.77 | Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). ( Helms, RW; Ware, RE, 2012) |
" Our results, while no longer the product of a randomized study because of the ethical concerns of withholding an efficacious treatment, suggest that long-term use of hydroxyurea is safe and might decrease mortality." | 2.75 | The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. ( Armstrong, FD; Ataga, K; Ballas, SK; Castro, O; DeCastro, L; Kutlar, A; McCarthy, WF; Smith, W; Steinberg, MH; Swerdlow, P; Waclawiw, MA, 2010) |
"Hydroxyurea has hematologic and clinical efficacy in sickle cell anemia (SCA), but its effects on transcranial Doppler (TCD) flow velocities remain undefined." | 2.73 | Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. ( Burgett, S; Mortier, NA; Schultz, WH; Ware, RE; Zimmerman, SA, 2007) |
"In the Stroke Prevention Trial for Sickle Cell Anemia Study, patients were randomized to receive long-term transfusion (CTX) or standard care (STC)." | 2.71 | Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. ( Adams, R; Brambilla, D; Morales, KH; Olivieri, N; Scher, CD; Styles, L; Wang, WC, 2005) |
"Stroke affects around 10% of children with sickle cell anaemia (HbSS)." | 2.66 | Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. ( Estcourt, LJ; Hopewell, S; Kohli, R; Trivella, M; Wang, WC, 2020) |
"Sickle cell disease is one of the commonest severe monogenic disorders in the world, due to the inheritance of two abnormal haemoglobin (beta globin) genes." | 2.55 | Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. ( Estcourt, LJ; Fortin, PM; Hopewell, S; Trivella, M; Wang, WC, 2017) |
"Sickle cell disease is a common and life-threatening haematological disorder that affects millions of people worldwide." | 2.55 | Sickle cell disease. ( Abboud, MR; de Montalembert, M; Tshilolo, L; Ware, RE, 2017) |
"Stroke is a significant cause of morbidity and mortality in children and adults with sickle cell disease." | 2.49 | Stroke in patients with sickle cell disease. ( Kwiatkowski, JL; Webb, J, 2013) |
"Stroke is one of the most devastating complications of sickle cell disease, but current research has led to improved understanding of its pathogenesis and to new approaches in the prevention of both primary and secondary stroke." | 2.44 | The pathophysiology, prevention, and treatment of stroke in sickle cell disease. ( Wang, WC, 2007) |
"Sickle cell disease is a recessively inherited condition in which synthesis of haemoglobin is abnormal." | 2.41 | Acute complications of sickle cell disease in children. ( , 2001) |
"Venous thrombosis is more frequent in PV than in ET; superficial or deep venous thromboses are seen." | 2.41 | [What vascular events suggest a myeloproliferative disorder?]. ( Caulier-Leleu, MT; Hachulla, E; Pasturel-Michon, U; Rose, C; Trillot, N, 2000) |
"Youths with sickle cell anemia (SCA) are at risk of pain crises, stroke, and early death." | 1.91 | Changes in Hydroxyurea Use Among Youths Enrolled in Medicaid With Sickle Cell Anemia After 2014 Revision of Clinical Guidelines. ( Anders, D; Cogan, LW; Dombkowski, KJ; Goel, A; Green, NS; Lisabeth, LD; Peng, HK; Reeves, SL; Wing, JJ, 2023) |
"Ischemic stroke is characterized by high morbidity, disability, and mortality." | 1.91 | Enhanced brain delivery of hypoxia-sensitive liposomes by hydroxyurea for rescue therapy of hyperacute ischemic stroke. ( Hong, Y; Hu, F; Jin, X; Ke, J; Li, S; Shang, X; Wang, K; Wen, L; Wu, X; Xu, Y; Yuan, H; Zhou, W, 2023) |
"A total of 200 children with sickle cell anemia completed neurocognitive testing (109 males, 91 females; mean age 12." | 1.72 | Neurocognitive functioning in children with sickle cell anemia and history of abnormal transcranial doppler ultrasonography. ( Gossett, J; Hankins, JS; Heitzer, AM; Kang, G; King, AA; Krull, K; Longoria, JN; Raches, D; Schreiber, J; Wang, W, 2022) |
"Hydroxyurea has been shown to positively modify sickle cell disease pathogenesis, but its use is low among Nigerian sickle cell anaemia (SCA) patients because of effectiveness and safety concerns." | 1.56 | Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria. ( Adekola, K; Afolaranmi, TO; Diaku-Akinwumi, IN; Ofakunrin, AOD; Oguche, S; Okpe, ES; Sagay, AS; Zoakah, AI, 2020) |
"Hydroxyurea (HU) has been shown to reduce elevated TCD velocities in children with SCD." | 1.51 | Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea. ( Asinobi, A; Brown, BJ; Esione, A; Ibeh, J; Lagunju, I; Oyinlade, AO; Sodeinde, OO, 2019) |
" These data nicely complement the recently published results from the phase 3 multicenter TCD With Transfusions Changing to Hydroxyurea (TWiTCH) study and suggest that it may be safe to carefully transition a subset of patients from chronic transfusions to hydroxyurea therapy." | 1.43 | Hydroxyurea for abnormal TCDs: safe to switch? ( McGann, PT, 2016) |
"Hydroxyurea-induced pneumonitis is unusual." | 1.40 | [Hydroxyurea-induced pneumonia]. ( Claeyssen, V; Decaux, O; Delaval, P; Desrues, B; Girard, A; Jouneau, S; Poullot, E; Ricordel, C, 2014) |
"Hydroxyurea is an antineoplastic agent commonly used to treat essential thrombocytosis." | 1.40 | Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis. ( Gupta, A; Karanth, SS; Prabhu, M, 2014) |
"Proper management of sickle cell anemia (SCA) begins with establishing the correct diagnosis early in life, ideally during the newborn period." | 1.39 | Current management of sickle cell anemia. ( McGann, PT; Nero, AC; Ware, RE, 2013) |
"Stroke and silent cerebral infarction were not related to clinical hematologic or HbF response to HU." | 1.39 | Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians. ( Calvaruso, G; Iannello, S; Maggio, A; Pecoraro, A; Rigano, P; Steinberg, MH, 2013) |
"Sickle cell disease is characterized by phenotypic heterogeneity and many genetic modifiers have been identified with elevated Hb F being the most recognized ameliorating factor." | 1.37 | Limitations of Hb F as a phenotypic modifier in sickle cell disease: study of Kuwaiti Arab patients. ( Adekile, AD, 2011) |
"Two patients presenting homozygous hemoglobin S disease died due to septicemia due to non-compliance with antibiotic therapy in one case and severe anemia in one case." | 1.36 | Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management. ( Cotton, F; Dedeken, L; Dresse, MF; Ferster, A; Gulbis, B; Heijmans, C; Ketelslegers, O; Lê, PQ; Vanderfaeillie, A; Vermylen, C; Vertongen, F, 2010) |
"Sickle cell disease is the most common inherited disease in the U." | 1.35 | The clinical care of adult patients with sickle cell disease. ( Howard, J; Olujohungbe, A, 2008) |
"(1) Stroke secondary to PV should be treated with stroke regimen as well as PV therapy, and hydroxycarbamide might have stable benefit and few side effects." | 1.33 | [The diagnosis and treatment of polycythemia rubra vera manifesting as acute cerebral stroke]. ( Ji, XM; Jia, JP; Li, LM; Meng, R; Yang, BF; Zhou, J, 2006) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (0.75) | 18.2507 |
2000's | 32 (23.88) | 29.6817 |
2010's | 63 (47.01) | 24.3611 |
2020's | 38 (28.36) | 2.80 |
Authors | Studies |
---|---|
Hsu, P | 1 |
Gay, JC | 1 |
Lin, CJ | 1 |
Rodeghier, M | 9 |
DeBaun, MR | 23 |
Cronin, RM | 2 |
Abdullahi, SU | 10 |
Jibir, BW | 3 |
Bello-Manga, H | 5 |
Gambo, S | 7 |
Inuwa, H | 2 |
Tijjani, AG | 1 |
Idris, N | 3 |
Galadanci, A | 2 |
Hikima, MS | 1 |
Galadanci, N | 1 |
Borodo, A | 1 |
Tabari, AM | 2 |
Haliru, L | 4 |
Suleiman, A | 2 |
Ibrahim, J | 1 |
Greene, BC | 2 |
Ghafuri, DL | 4 |
Slaughter, JC | 1 |
Kirkham, FJ | 5 |
Neville, K | 4 |
Kassim, A | 1 |
Trevathan, E | 2 |
Jordan, LC | 9 |
Aliyu, MH | 7 |
Farouk, B | 1 |
Bahago, GY | 1 |
Sani, AM | 1 |
Bauman, AA | 1 |
King, AA | 3 |
Smart, LR | 2 |
Ambrose, EE | 2 |
Balyorugulu, G | 1 |
Songoro, P | 2 |
Shabani, I | 1 |
Komba, P | 1 |
Charles, M | 2 |
Howard, TA | 2 |
McElhinney, KE | 1 |
O'Hara, SM | 1 |
Odame, J | 1 |
Nakafeero, M | 2 |
Adams, J | 1 |
Stuber, SE | 3 |
Lane, A | 5 |
Latham, TS | 3 |
Makubi, AN | 2 |
Ware, RE | 21 |
Longoria, JN | 1 |
Wang, W | 1 |
Kang, G | 2 |
Gossett, J | 1 |
Krull, K | 1 |
Raches, D | 1 |
Schreiber, J | 1 |
Heitzer, AM | 1 |
Hankins, JS | 2 |
Rankine-Mullings, AE | 1 |
Nevitt, SJ | 1 |
Runge, A | 1 |
Brazel, D | 1 |
Pakbaz, Z | 1 |
Sunusi, S | 1 |
Abba, MS | 2 |
Sani, S | 1 |
Inuwa, HA | 1 |
Gambo, A | 1 |
Musa, B | 1 |
Covert Greene, BV | 1 |
Kassim, AA | 6 |
Hussaini, N | 1 |
Ciobanu, M | 1 |
Wuichet, K | 1 |
Hodges, B | 1 |
Chopra, M | 1 |
He, J | 1 |
Niu, X | 1 |
Wilkerson, K | 1 |
Klein, LJ | 3 |
Stallings, VA | 3 |
Acra, S | 3 |
Tang, AY | 1 |
Zhou, M | 1 |
Maillis, AN | 1 |
Lai, KW | 1 |
Lane, PA | 1 |
Snyder, AB | 1 |
Namazzi, R | 1 |
Opoka, R | 1 |
Conroy, AL | 1 |
Datta, D | 1 |
Tagoola, A | 1 |
Bond, C | 1 |
Goings, MJ | 1 |
Ryu, MS | 1 |
Cusick, SE | 1 |
Krebs, NF | 1 |
Jang, JH | 1 |
Tu, W | 1 |
John, CC | 2 |
Quinn, CT | 2 |
Lane, AC | 1 |
Diop, S | 1 |
de Montalembert, M | 3 |
Reeves, SL | 1 |
Peng, HK | 1 |
Wing, JJ | 1 |
Cogan, LW | 1 |
Goel, A | 1 |
Anders, D | 1 |
Green, NS | 1 |
Lisabeth, LD | 1 |
Dombkowski, KJ | 1 |
Oguro, H | 1 |
Takahashi, T | 1 |
Wang, K | 1 |
Zhou, W | 1 |
Jin, X | 1 |
Shang, X | 1 |
Wu, X | 1 |
Wen, L | 1 |
Li, S | 1 |
Hong, Y | 1 |
Ke, J | 1 |
Xu, Y | 1 |
Yuan, H | 1 |
Hu, F | 1 |
Karkoska, KA | 1 |
Gollamudi, J | 1 |
Hyacinth, HI | 1 |
Galadanci, AA | 1 |
Galadanci, NA | 5 |
Ali Abubakar, SA | 1 |
Kabo, NA | 1 |
Bashir, I | 1 |
Galadanci, JA | 1 |
Monus, T | 1 |
Howell, CM | 1 |
Ofakunrin, AOD | 1 |
Oguche, S | 1 |
Adekola, K | 1 |
Okpe, ES | 1 |
Afolaranmi, TO | 1 |
Diaku-Akinwumi, IN | 1 |
Zoakah, AI | 1 |
Sagay, AS | 1 |
Opoka, RO | 1 |
Hume, HA | 1 |
Williams, O | 1 |
Tymon, J | 1 |
Kasirye, P | 1 |
Ndugwa, CM | 1 |
Hasson, C | 1 |
Veling, L | 1 |
Rico, J | 1 |
Mhaskar, R | 1 |
Estcourt, LJ | 5 |
Kimber, C | 1 |
Hopewell, S | 5 |
Trivella, M | 4 |
Doree, C | 2 |
Abboud, MR | 4 |
Schatz, J | 1 |
Vichinsky, E | 1 |
Fox, CK | 1 |
McKinstry, RC | 2 |
Telfer, P | 1 |
Kraut, MA | 1 |
Daraz, L | 1 |
Murad, MH | 1 |
Nickel, RS | 1 |
Margulies, S | 1 |
Frazer, B | 1 |
Luban, NLC | 2 |
Webb, J | 2 |
Novelli, EM | 1 |
Ali Abubakar, S | 1 |
Wudil Jibir, B | 2 |
Aminu, H | 1 |
Tijjani, A | 2 |
Tabari, MA | 3 |
Borodo, AM | 1 |
Belonwu, R | 3 |
Salihu, AS | 1 |
Covert C Greene, BV | 1 |
Kohli, R | 1 |
Wang, WC | 6 |
Steinberg, MH | 4 |
Lagunju, IA | 2 |
Labaeka, A | 1 |
Ibeh, JN | 1 |
Orimadegun, AE | 1 |
Brown, BJ | 4 |
Sodeinde, OO | 3 |
Allali, S | 1 |
Taylor, M | 1 |
Brice, J | 1 |
Dambatta, AH | 1 |
Galadanci, J | 1 |
Suleiman, AA | 1 |
Gambo, AI | 1 |
Khalifa, Y | 1 |
Abdulrasheed, S | 1 |
Zakari, MA | 1 |
Baumann, AA | 1 |
Bhattacharya, P | 1 |
Sarmah, D | 1 |
Dave, KR | 1 |
Goswami, A | 1 |
Watanabe, M | 1 |
Wang, X | 1 |
Kalia, K | 1 |
Plesnila, N | 1 |
Yavagal, DR | 1 |
Alvarez, O | 4 |
Estepp, JH | 1 |
Cong, Z | 1 |
Agodoa, I | 1 |
Ding, J | 1 |
McCarville, MB | 1 |
Rankine-Mullings, A | 1 |
Reid, M | 3 |
Soares, D | 1 |
Taylor-Bryan, C | 1 |
Wisdom-Phipps, M | 1 |
Aldred, K | 1 |
Latham, T | 3 |
Schultz, WH | 10 |
Knight-Madden, J | 3 |
Badaloo, A | 1 |
Adams, RJ | 6 |
Mayer, SL | 1 |
Fields, ME | 3 |
Hulbert, ML | 2 |
Umar Abdullahi, S | 1 |
Vance, LD | 1 |
Musa Tabari, A | 1 |
Ali, S | 1 |
Salihu, A | 2 |
Amal Galadanci, A | 1 |
Shyr, Y | 2 |
Phillips, S | 2 |
Covert, BV | 2 |
Fortin, PM | 3 |
Schoenfeld, J | 1 |
Tulbert, BH | 1 |
Cusack, CA | 1 |
McGann, PT | 3 |
Williams, TN | 1 |
Olupot-Olupot, P | 1 |
Tomlinson, GA | 1 |
Luís Reis da Fonseca, J | 1 |
Kitenge, R | 1 |
Mochamah, G | 1 |
Wabwire, H | 1 |
Stuber, S | 2 |
McElhinney, K | 1 |
Aygun, B | 6 |
Santos, B | 1 |
Tshilolo, L | 2 |
Lagunju, I | 2 |
Oyinlade, AO | 1 |
Asinobi, A | 1 |
Ibeh, J | 1 |
Esione, A | 1 |
Barbui, T | 1 |
Finazzi, G | 1 |
Vannucchi, AM | 1 |
De Stefano, V | 1 |
Reid, ME | 1 |
Casella, JF | 2 |
Brambilla, DJ | 1 |
Strouse, JJ | 1 |
Maier, P | 1 |
Dlugash, R | 1 |
Avadhani, R | 1 |
Vermillion, K | 1 |
Tonascia, J | 1 |
Voeks, JH | 1 |
Hanley, DF | 1 |
Thompson, RE | 1 |
Lehmann, HP | 1 |
Sánchez, LM | 1 |
Nieves, RM | 1 |
Luden, JR | 1 |
Urcuyo, GS | 1 |
Berges, ME | 1 |
Florencio, C | 1 |
Gonzalez, C | 1 |
Del Villar, P | 1 |
Schultz, W | 2 |
Jeste, N | 1 |
Mena, R | 1 |
Núñez, RM | 1 |
Figueroa, CAP | 1 |
García-Perdomo, HA | 1 |
Guilliams, KP | 2 |
Dowling, MM | 1 |
Ragan, D | 1 |
Binkley, MM | 1 |
Mirro, A | 1 |
Fellah, S | 1 |
Blinder, M | 1 |
Eldeniz, C | 1 |
Vo, K | 1 |
Shimony, JS | 1 |
Chen, Y | 1 |
An, H | 1 |
Lee, JM | 1 |
Ford, AL | 1 |
Hirtz, D | 1 |
Ojewunmi, OO | 1 |
Adeyemo, TA | 1 |
Ayinde, OC | 1 |
Iwalokun, B | 1 |
Adekile, A | 1 |
Nero, AC | 1 |
Sheth, S | 1 |
Licursi, M | 1 |
Bhatia, M | 1 |
Kwiatkowski, JL | 3 |
Rigano, P | 1 |
Pecoraro, A | 1 |
Calvaruso, G | 1 |
Iannello, S | 1 |
Maggio, A | 1 |
Yovetich, NA | 1 |
Scott, JP | 2 |
Owen, W | 2 |
Miller, ST | 4 |
Lockhart, A | 2 |
Flanagan, J | 1 |
Bonner, M | 1 |
Mueller, BU | 2 |
Dwan, K | 1 |
Karanth, SS | 1 |
Gupta, A | 1 |
Prabhu, M | 1 |
Madden, NA | 1 |
Jones, GL | 1 |
Kalpatthi, R | 1 |
Woods, G | 1 |
Girard, A | 1 |
Ricordel, C | 1 |
Poullot, E | 1 |
Claeyssen, V | 1 |
Decaux, O | 1 |
Desrues, B | 1 |
Delaval, P | 1 |
Jouneau, S | 1 |
Helton, KJ | 2 |
Kesler, KL | 1 |
Driscoll, C | 1 |
Heeney, MM | 3 |
Jackson, SM | 1 |
Krishnamurti, L | 2 |
Sarnaik, SA | 1 |
Ballas, SK | 2 |
Martinez, U | 1 |
Savage, M | 1 |
Abubakar, S | 1 |
Kirkham, F | 1 |
Inusa, B | 1 |
Sodeinde, O | 1 |
Cunningham-Myrie, C | 1 |
Abdulkadri, A | 1 |
Waugh, A | 1 |
Bortolusso Ali, S | 1 |
King, LG | 1 |
Wood, JC | 2 |
Pressel, S | 2 |
Rogers, ZR | 6 |
Odame, I | 2 |
Lee, MT | 2 |
Owen, WC | 1 |
Cohen, AR | 3 |
St Pierre, T | 1 |
Davis, BR | 3 |
Pressel, SL | 1 |
Imran, H | 2 |
Luchtman-Jones, L | 3 |
Thompson, AA | 4 |
Fuh, B | 2 |
Chaturvedi, S | 1 |
Brown, RC | 1 |
Sarnaik, S | 2 |
George, A | 1 |
Hilliard, L | 2 |
Gauger, C | 2 |
Piccone, C | 1 |
Jackson, S | 2 |
Roberts, C | 1 |
Kalfa, TA | 1 |
Nelson, S | 1 |
Nottage, K | 1 |
Rhodes, M | 1 |
Rothman, JA | 1 |
Roberts, D | 1 |
Coleman, J | 1 |
Bonner, MJ | 1 |
Kutlar, A | 2 |
Patel, N | 1 |
Wood, J | 1 |
Piller, L | 1 |
Wei, P | 1 |
Luden, J | 1 |
Mortier, NA | 4 |
Bernaudin, F | 1 |
Verlhac, S | 1 |
Arnaud, C | 1 |
Kamdem, A | 1 |
Hau, I | 1 |
Leveillé, E | 1 |
Vasile, M | 1 |
Kasbi, F | 1 |
Madhi, F | 1 |
Fourmaux, C | 1 |
Biscardi, S | 1 |
Gluckman, E | 1 |
Socié, G | 1 |
Dalle, JH | 1 |
Epaud, R | 1 |
Pondarré, C | 1 |
Couque, N | 1 |
Girard, D | 1 |
Ducrocq, R | 1 |
Boizeau, P | 1 |
Haouari, Z | 1 |
Missud, F | 1 |
Holvoet, L | 1 |
Ithier, G | 1 |
Belloy, M | 1 |
Odièvre, MH | 1 |
Benemou, M | 1 |
Benhaim, P | 1 |
Retali, B | 1 |
Bensaid, P | 1 |
Monier, B | 1 |
Brousse, V | 2 |
Amira, R | 1 |
Orzechowski, C | 1 |
Lesprit, E | 1 |
Mangyanda, L | 1 |
Garrec, N | 1 |
Elion, J | 1 |
Alberti, C | 1 |
Baruchel, A | 1 |
Benkerrou, M | 2 |
Meier, ER | 2 |
Rampersad, A | 1 |
Ozsahin, H | 1 |
Sidani, CA | 1 |
Ballourah, W | 1 |
El Dassouki, M | 1 |
Muwakkit, S | 1 |
Dabbous, I | 1 |
Dahoui, H | 1 |
Al-Kutoubi, A | 1 |
Trompeter, S | 1 |
Roberts, I | 1 |
Olujohungbe, A | 1 |
Howard, J | 1 |
Suliman, H | 1 |
Wali, Y | 1 |
Al Saadoon, M | 1 |
Zechariah, M | 1 |
William, RR | 1 |
Gujjar, A | 1 |
Pathare, A | 1 |
Sandhu, G | 1 |
Ranade, A | 1 |
Siddiqi, S | 1 |
Balderacchi, JL | 1 |
Verduzco, LA | 1 |
Nathan, DG | 1 |
McCarthy, WF | 1 |
Castro, O | 1 |
Armstrong, FD | 1 |
Smith, W | 1 |
Ataga, K | 1 |
Swerdlow, P | 1 |
DeCastro, L | 1 |
Waclawiw, MA | 1 |
Greenway, A | 1 |
Thornburg, CD | 1 |
Lê, PQ | 3 |
Ferster, A | 5 |
Cotton, F | 1 |
Vertongen, F | 1 |
Vermylen, C | 3 |
Vanderfaeillie, A | 1 |
Dedeken, L | 1 |
Heijmans, C | 2 |
Ketelslegers, O | 1 |
Dresse, MF | 3 |
Gulbis, B | 3 |
Coates, TD | 1 |
Yovetich, N | 1 |
Iyer, RV | 1 |
Waclawiw, M | 1 |
Helms, RW | 3 |
Ali, SB | 1 |
Moosang, M | 1 |
King, L | 1 |
Adekile, AD | 1 |
Lebensburger, JD | 1 |
Wruck, LM | 1 |
Brown, C | 1 |
Iyer, R | 1 |
Bartolucci, P | 1 |
Galactéros, F | 1 |
Miller, JL | 1 |
McCavit, TL | 1 |
Verdure, P | 1 |
Lefaucheur, R | 1 |
Guegan-Massardier, E | 1 |
Triquenot-Bagan, A | 1 |
Gerardin, E | 1 |
Maltête, D | 1 |
Desai, PC | 1 |
Deal, AM | 1 |
Brittain, JE | 1 |
Jones, S | 1 |
Hinderliter, A | 1 |
Ataga, KI | 1 |
Naganuma, M | 1 |
Isoda, K | 1 |
Nishi, S | 1 |
Ito, K | 1 |
Hirano, T | 1 |
Cherry, MG | 1 |
Greenhalgh, J | 1 |
Osipenko, L | 1 |
Venkatachalam, M | 1 |
Boland, A | 1 |
Dundar, Y | 1 |
Marsh, K | 1 |
Dickson, R | 1 |
Rees, DC | 1 |
Blinder, MA | 1 |
Vekeman, F | 1 |
Sasane, M | 1 |
Trahey, A | 1 |
Paley, C | 1 |
Duh, MS | 1 |
Sumoza, A | 1 |
de Bisotti, R | 1 |
Sumoza, D | 1 |
Fairbanks, V | 1 |
Amrolia, PJ | 1 |
Almeida, A | 1 |
Davies, SC | 1 |
Roberts, IA | 1 |
Agarwal, MB | 1 |
Atweh, GF | 1 |
DeSimone, J | 1 |
Saunthararajah, Y | 1 |
Fathallah, H | 1 |
Weinberg, RS | 1 |
Nagel, RL | 1 |
Fabry, ME | 1 |
Buchanan, GR | 2 |
Zimmerman, SA | 3 |
Sylvestre, PB | 1 |
Davis, JS | 1 |
Treem, WR | 1 |
Haberman, D | 1 |
Dufour, D | 2 |
Christophe, C | 1 |
Kagambega, F | 1 |
Corazza, F | 2 |
Devalck, C | 2 |
Hunninck, K | 2 |
Klein, A | 1 |
Loop, M | 1 |
Maes, P | 1 |
Philippet, P | 2 |
Sariban, E | 2 |
Van Geet, C | 2 |
Morales, KH | 1 |
Scher, CD | 1 |
Styles, L | 1 |
Olivieri, N | 1 |
Adams, R | 1 |
Brambilla, D | 1 |
Okpala, IE | 1 |
Meng, R | 1 |
Zhou, J | 1 |
Ji, XM | 1 |
Li, LM | 1 |
Jia, JP | 1 |
Yang, BF | 1 |
Shull, EP | 1 |
Ahmad, N | 1 |
Lee, NJ | 1 |
Couillard, S | 1 |
Girot, R | 1 |
Bader-Meunier, B | 1 |
Burgett, S | 1 |
Field, JJ | 1 |
Lefèvre, N | 1 |
Powars, DR | 1 |
Schaefer, U | 1 |
Micke, O | 1 |
Schueller, P | 1 |
Willich, N | 1 |
Hachulla, E | 1 |
Rose, C | 1 |
Trillot, N | 1 |
Caulier-Leleu, MT | 1 |
Pasturel-Michon, U | 1 |
Tahriri, P | 1 |
Sturbois, G | 1 |
Fondu, P | 1 |
Feremans, W | 1 |
Toppet, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial[NCT00072761] | Phase 3 | 196 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
Primary Prevention of Stroke in Children With Sickle Cell Disease in Sub-Saharan Africa II[NCT02560935] | Phase 3 | 440 participants (Actual) | Interventional | 2016-07-19 | Completed | ||
Hydroxyurea for Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa[NCT02675790] | Phase 3 | 120 participants (Anticipated) | Interventional | 2017-01-31 | Completed | ||
"Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda: A Single Arm Open Label Trial, BRAIN SAFE II"[NCT04750707] | Phase 3 | 270 participants (Actual) | Interventional | 2021-03-09 | Active, not recruiting | ||
REALIZING EFFECTIVENESS ACROSS CONTINENTS WITH HYDROXYUREA (REACH): A PHASE I/II PILOT STUDY OF HYDROXYUREA FOR CHILDREN WITH SICKLE CELL ANEMIA[NCT01966731] | Phase 1/Phase 2 | 635 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
Stroke With Transfusions Changing to Hydroxyurea[NCT00122980] | Phase 3 | 134 participants (Actual) | Interventional | 2006-10-31 | Terminated (stopped due to The study has been stopped due to safety and futility concerns.) | ||
Physical Rehabilitation in Adults With Sickle Cell Anemia: Effects on Muscle Function, Functional Capacity and Quality of Life[NCT04705792] | 40 participants (Anticipated) | Interventional | 2020-01-31 | Recruiting | |||
TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Phase III Randomized Trial to Compare Standard Therapy (Erythrocyte Transfusions) With Alternative Therapy (Hydroxyurea) for the Maintenance of Lowered TCD Velocities in Pediatric Subjects With Sic[NCT01425307] | Phase 3 | 159 participants (Actual) | Interventional | 2011-08-31 | Terminated (stopped due to The study was stopped early due to successfully meeting the primary endpoint) | ||
Monocytic Expression of Heme Oxidase-1 (HO-1) in Sickle Cell Patients and Correlation With the Humoral Immune Response to Vaccine and With Allo-immunization[NCT03111589] | 102 participants (Actual) | Interventional | 2016-10-31 | Completed | |||
A Pilot Study of the Use of Oral Ketamine for Treatment of Vaso-Occlusive Pain in Adolescents and Young Adults[NCT05378555] | Phase 3 | 10 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
Prospective Clinical Study on Early Inflammatory, Cell Adhesion and Hemostatic Plasmatic Markers of Endothelial Dysfunction in Children With Sickle Cell Disease (SCD)[NCT04839159] | 41 participants (Anticipated) | Interventional | 2012-05-10 | Active, not recruiting | |||
Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients[NCT02565082] | 64 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell[NCT02561312] | 9 participants (Actual) | Observational | 2015-09-30 | Completed | |||
Obesity in Pediatric Sickle Cell Disease: A New Phenomenon[NCT04676113] | 100 participants (Actual) | Observational | 2021-03-01 | Completed | |||
[NCT00000592] | Phase 3 | 0 participants | Interventional | 1994-07-31 | Completed | ||
[NCT00006182] | Phase 3 | 0 participants | Interventional | 2000-07-31 | Completed | ||
Comparison of Sub-dissociative Intranasal Ketamine Plus Standard Pain Therapy Versus Standard Pain Therapy in the Treatment of Pediatric Sickle Cell Disease Vasoocclusive Crises in Resource-limited Settings: a Multi-centered, Randomized, Controlled Trial[NCT02573714] | 160 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
Quantitative and Prognostic Evaluation of Dense Red Blood Cells in Sickle Cell Children: Single-center Study From the Creteil (France) Pediatric Cohort[NCT02887118] | 82 participants (Actual) | Observational | 2015-12-31 | Terminated (stopped due to The recruiting centre was no longer presenting new patients for inclusion) | |||
Hydroxyurea to Prevent Central Nervous System (CNS) Complications of Sickle Cell Disease in Children[NCT01389024] | Phase 2 | 28 participants (Actual) | Interventional | 2012-08-16 | Completed | ||
[NCT00005327] | 0 participants | Observational | 1993-04-30 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The primary end point was the recurrence of infarct or hemorrhage as determined by neuroimaging, clinical evidence of permanent neurologic injury, or both. A new infarct had to meet the criteria for a silent cerebral infarction; an enlarged silent cerebral infarct was defined as a previously identified silent cerebral infarct that increased by at least 3 mm along any linear dimension in any plane on MRI. (NCT00072761)
Timeframe: From study entry to study exit
Intervention | infarct recurrence per 100 person years (Number) |
---|---|
Transfusion Group | 2.0 |
Observation Group | 4.8 |
An expected toxicity rate of 20% and acceptable toxicity rate of 30% were used for statistical calculations. After 53 participants at each site complete 3 months of therapy, if ≤ 15 participants have hematologic toxicity there is no early evidence against safety. If ≥ 15 of the initial participants experience toxicity, this is early evidence against safety. Future participants will begin at a lower dose of hydroxyurea (10 ± 2.5 mg/kg), with another 53 participants recruited of the same safety analysis. Upon final analysis of 133 participants at the same starting dose, safety for fixed-dose hydroxyurea can be concluded. (NCT01966731)
Timeframe: 3 months
Intervention | percentage of participants (Number) |
---|---|
Hydroxyurea | 5.1 |
The Barthel Index is a measure of activities of daily living (ADL) and assesses the degree of disability in a particular participant. The index records indicators of independence in terms of the disability caused by impairments, such as those that may be sequelae of stroke. The index was used as a record of what the participant did, not as a record of what the participant could do. Barthel scores range from 0 to 100, with higher scores indicating greater independence in daily living activities (caring for oneself). (NCT00122980)
Timeframe: Baseline and study exit after up to 30-month treatment period (due to study termination)
Intervention | units on a scale (Mean) |
---|---|
Hydroxyurea/Phlebotomy | -0.33 |
Transfusion/Chelation | -0.53 |
(NCT00122980)
Timeframe: Baseline to end of study participation (up to 136 weeks)
Intervention | cm (Mean) |
---|---|
Hydroxyurea/Phlebotomy | 4.40 |
Transfusion/Chelation | 6.61 |
(NCT00122980)
Timeframe: baseline to end of study participation (up to 136 weeks)
Intervention | kg (Mean) |
---|---|
Hydroxyurea/Phlebotomy | 3.83 |
Transfusion/Chelation | 6.36 |
LIC change-from-baseline is the second component of the composite primary endpoint. LIC was measured by quantitative liver biopsy at baseline and at 30 months or exit from the study.LIC values were transformed into Log10 values prior to computing the change from baseline. (NCT00122980)
Timeframe: Because the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 30 Months)
Intervention | mg ferritin/gram dry weight liver (Log Mean) |
---|---|
Hydroxyurea/Phlebotomy | -0.006 |
Transfusion/Chelation | -0.120 |
This test is designed to assess both broad and narrow cognitive abilities in children age 4 years and above as well as to measure major aspects of academic achievement in persons aged 2-90 years. Higher scores mean better abilities/achievements. Scaled scores range from 0-100. (NCT00122980)
Timeframe: Baseline and study exit after up to 30-month treatment period (due to study termination)
Intervention | units on a scale (Mean) |
---|---|
Hydroxyurea/Phlebotomy | 1.829 |
Transfusion/Chelation | -2.487 |
Secondary stroke is the first component of the composite primary endpoint and considers the number of participants with recurrent secondary stroke events during 30 months of treatment. Stroke was defined as any clinical event with brain injury due to vascular disease. All neurological events underwent formal stroke adjudication. (NCT00122980)
Timeframe: Because the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 30 Months)
Intervention | participants (Number) | |
---|---|---|
Stroke | No Stroke | |
Hydroxyurea/Phlebotomy | 7 | 60 |
Transfusion/Chelation | 0 | 66 |
The PedsQLTM Measurement Model is a modular approach to measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions. It has a Likert 5-points scale (never to almost always) which were transformed to a 0 to 100 scale based on the PedsQL scoring algorithms, higher scores indicating better quality of life characteristics. (NCT00122980)
Timeframe: Baseline, midpoint (week 64), and study exit (up to 30 months of treatment)
Intervention | units on a scale (Mean) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Midpoint: Emotional Functioning Score (n=47, 57) | Exit: Emotional Functioning Score (n=55, 54) | Midpoint: Physical Functioning Score (n=47, 57) | Exit: Physical Functioning Score (n=55, 54) | Midpoint: School Functioning Score (n=47, 57) | Exit: School Functioning Score (n=55, 53) | Midpoint: Social Functioning Score (n=46, 57) | Exit: Social Functioning Score (n=54, 54) | Midpoint: Total Functioning Score (n=47, 57) | Exit: Total Functioning Score (n=55, 54) | Midpoint: Psychosocial Health Summary (n=47, 57) | Exit: Psychosocial Health Summary Score (n=57, 54) | |
Hydroxyurea/Phlebotomy | 1.06 | 3.82 | 0.46 | 3.41 | -1.03 | 1.76 | 2.39 | 3.13 | 0.35 | 2.90 | 0.28 | 2.65 |
Transfusion/Chelation | 3.51 | 3.80 | 3.18 | 2.03 | 4.56 | 2.74 | 1.84 | 2.87 | 3.26 | 2.62 | 3.30 | 2.93 |
The PedsQL(TM) Measurement Model is a modular approach to measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions. It has a Likert 5-points scale (never to almost always) which were transformed to a 0 to 100 scale based on the PedsQL scoring algorithms, higher scores indicating better quality of life characteristics. (NCT00122980)
Timeframe: Baseline, mid-point (week 64), and study exit after up to 30-month treatment period (due to study termination)
Intervention | units on a scale (Mean) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Mid-point: Emotional Functioning Score (n=43,54) | Exit: Emotional Functioning Score (n=52, 54) | Mid-point: Physical Functioning Score (n=43,64) | Exit: Physical Functioning Score (n=53, 54) | Mid-point: School Functioning (n=43, 54) | Exit: School Functioning (n=51,53) | Mid-point : Social Functioning Score (n=42, 54) | Exit : Social Functioning Score (n=53, 54) | Mid-point: Total Functioning Score (n=43, 54) | Exit: Total Functioning Score (n=53, 54) | Mid-point: Psychosocial Health Summary (n=43,54) | Exit: Psychosocial Health Summary (n=53, 54) | |
Hydroxyurea/Phlebotomy | -0.99 | -1.25 | -1.71 | 2.27 | 3.14 | -0.29 | 3.69 | 2.67 | 0.39 | 1.13 | 1.61 | 0.33 |
Transfusion/Chelation | 5.56 | 5.65 | -0.57 | -0.98 | -3.34 | 2.83 | -0.35 | -1.11 | 0.20 | 1.09 | 0.59 | 2.11 |
This test is designed to assess both broad and narrow cognitive abilities in children age 4 years and above as well as to measure major aspects of academic achievement in persons aged 2-90 years. Scaled scores range from 0-100. Higher scores mean better abilities/achievements. (NCT00122980)
Timeframe: Baseline and study exit after up to 30-month treatment period (due to study termination)
Intervention | units on a scale (Mean) | ||||||
---|---|---|---|---|---|---|---|
General intellectual ability (n=33, 35) | Processing speed (n=35, 33) | Working memory (n=33, 34) | Broad attention (n=31, 33) | Executive processes (n=32, 33) | Broad reading (n=34, 33) | Broad math (n=34, 33) | |
Hydroxyurea/Phlebotomy | -1.64 | -0.80 | -7.67 | -4.36 | -0.72 | -0.29 | -3.53 |
Transfusion/Chelation | -3.00 | 2.06 | -2.65 | -0.49 | -1.15 | -0.94 | -5.76 |
This secondary objective will compare standard to alternative therapy for hepatic iron overload. (NCT01425307)
Timeframe: Baseline and 24 months
Intervention | mg FE per g dry weight liver (Mean) |
---|---|
Standard Therapy | 2.4 |
Treatment Arm | -1.9 |
This secondary objective will compare standard to alternative therapy for hepatic iron overload. (NCT01425307)
Timeframe: Baseline and 24 months
Intervention | ng per mL (Mean) |
---|---|
Standard Therapy | -38 |
Treatment Arm | -1805 |
The primary endpoint for the TWiTCH trial was the difference between the treatment groups of the maximum TCD TAMV on the index side, calculated from a mixed model. The index side is the side with the higher mean (averaged over baseline evaluations) of the maximum (over arteries on that side) TCD time-averaged velocity. Values of the TAMV on the index site were obtained at clinic visits during baseline and during the treatment period. (NCT01425307)
Timeframe: Since the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 24 Months).
Intervention | cm/sec (Mean) |
---|---|
Treatment Arm | 138 |
Standard Therapy | 143 |
We will evaluate the number of participants consented and fully screened that were randomized to hydroxyurea or placebo. (NCT01389024)
Timeframe: 6 months
Intervention | Participants (Count of Participants) |
---|---|
Participants Completing Screening Procedures | 12 |
A composite of abnormally elevated cerebral blood flow velocity as measured by transcranial Doppler ultrasound, silent cerebral infarct, or stroke. (NCT01389024)
Timeframe: 3 years
Intervention | Participants (Count of Participants) |
---|---|
Hydroxyurea | 1 |
Placebo | 4 |
Number of sedated MRIs resulting in serious adverse events. Participants can have multiple MRIs performed. (NCT01389024)
Timeframe: 3 years
Intervention | MRIs (Count of Units) |
---|---|
MRIs With Sedation. | 3 |
Number of MRIs resulting in serious adverse events. Participants can have multiple MRIs performed. (NCT01389024)
Timeframe: 3 years
Intervention | MRIs (Count of Units) |
---|---|
Participants Undergoing MRIs | 3 |
44 reviews available for hydroxyurea and Apoplexy
Article | Year |
---|---|
Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Topics: Acute Chest Syndrome; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Hemoglobin, Sickle; Hu | 2022 |
Stroke in sickle cell disease and the promise of recent disease modifying agents.
Topics: Adult; Anemia, Sickle Cell; Anticoagulants; Aspirin; Cerebral Infarction; Humans; Hydroxyurea; Strok | 2022 |
Molecular and environmental contributors to neurological complications in sickle cell disease.
Topics: Anemia, Sickle Cell; Blood Transfusion; Cognitive Dysfunction; Humans; Hydroxyurea; Stroke | 2023 |
Current and emerging treatments for sickle cell disease.
Topics: Acute Chest Syndrome; Acute Disease; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Bacterial Agents; | 2019 |
The role of hydroxyurea to prevent silent stroke in sickle cell disease: Systematic review and meta-analysis.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Humans; Hydroxyurea; Stroke | 2019 |
Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Brain Infarction; Cause of Death; Child; Cogni | 2020 |
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Child, Preschool; Ea | 2020 |
Fetal hemoglobin in sickle cell anemia.
Topics: Anemia, Sickle Cell; beta-Globins; Fetal Hemoglobin; gamma-Globins; Gene Editing; Gene Expression Re | 2020 |
Stroke and stroke prevention in sickle cell anemia in developed and selected developing countries.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Developing Countries; Humans; Hydroxyurea; Stroke; | 2021 |
Neurologic and Cognitive Outcomes in Sickle Cell Disease from Infancy through Adolescence.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Cognition; Humans; Hy | 2021 |
Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Brain Infarction; Cause of Death; Child; Cogni | 2017 |
Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Erythrocyte Transfusion; Humans; Hydrox | 2018 |
Hydroxyurea can be used in children with sickle cell disease and cerebral vasculopathy for the prevention of chronic complications? A meta-analysis.
Topics: Anemia, Sickle Cell; Blood Transfusion; Child; Humans; Hydroxyurea; Stroke | 2020 |
Advances in Understanding Ischemic Stroke Physiology and the Impact of Vasculopathy in Children With Sickle Cell Disease.
Topics: Acute Disease; Anemia, Sickle Cell; Blood Transfusion; Brain Ischemia; Cerebral Arteries; Cerebrovas | 2019 |
Sickle Cell Disease and Stroke.
Topics: Anemia, Sickle Cell; Blood Transfusion; Cerebrovascular Circulation; Humans; Hydroxyurea; Stroke; Ul | 2019 |
Current perspectives of sickle cell disease in Nigeria: changing the narratives.
Topics: Anemia, Sickle Cell; Genetic Counseling; Hematopoietic Stem Cell Transplantation; Hemoglobins; Human | 2019 |
Sickle cell disease: time for a closer look at treatment options?
Topics: Africa; Anemia, Sickle Cell; Brain Damage, Chronic; Cardiovascular Diseases; Chelation Therapy; Chro | 2013 |
Stroke in patients with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Vessels; Brain; Cerebral Infarction; Humans; Hydroxy | 2013 |
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Topics: Anemia, Sickle Cell; Blood Transfusion; Child; Early Termination of Clinical Trials; Humans; Hydroxy | 2013 |
The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Chest Pain; Child; Hematopoietic Stem C | 2014 |
Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years.
Topics: Adult; Anemia, Sickle Cell; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antisickling Agents; Bloo | 2016 |
Pediatric sickle cell disease: past successes and future challenges.
Topics: Adolescent; Anemia, Sickle Cell; Blood Flow Velocity; Cerebrovascular Circulation; Child; Child, Pre | 2017 |
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Child, Preschool; Ea | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
MRI abnormalities in infants with sickle cell anemia-indication for preemptive therapy?
Topics: Anemia, Sickle Cell; Antisickling Agents; Brain; Clinical Trials as Topic; Humans; Hydroxyurea; Infa | 2008 |
Haemoglobin F modulation in childhood sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Azacitidine; Butyrates; Child; Clinical Trials as T | 2009 |
Sickle cell disease and stroke.
Topics: Anemia, Sickle Cell; Anti-Inflammatory Agents; Antisickling Agents; Blood Transfusion; Bone Marrow T | 2009 |
What is the evidence for using hydroxyurea for secondary stroke prevention?
Topics: Blood Transfusion; Child; Humans; Hydroxyurea; Male; Secondary Prevention; Stroke | 2011 |
Prospects for primary stroke prevention in children with sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Bacterial Infections; Blood Transfusion; Brain | 2012 |
Clinical management of adult sickle-cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Hypertension, Pulmonary; Kidney Disea | 2012 |
Sickle cell disease in children.
Topics: Anemia, Sickle Cell; Blood Transfusion; Child; Child, Preschool; Genetic Predisposition to Disease; | 2012 |
Sickle cell disease.
Topics: Acute Pain; Anemia, Sickle Cell; Antisickling Agents; Bone Marrow Transplantation; Erythrocyte Trans | 2012 |
The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Bone Marrow Transplantation; Cerebrovas | 2012 |
Therapeutic challenges in childhood sickle cell disease. Part 2: a problem-orientated approach.
Topics: Anemia, Sickle Cell; Antisickling Agents; Bone Marrow Transplantation; Central Nervous System Diseas | 2003 |
Advances in management of sickle cell disease.
Topics: Acute Disease; Adolescent; Anemia, Sickle Cell; Antisickling Agents; Bacterial Infections; Blood Tra | 2003 |
Hemoglobinopathies.
Topics: Animals; Azacitidine; Butyrates; Cerebral Hemorrhage; Decitabine; Disease Models, Animal; DNA Methyl | 2003 |
Predicting clinical severity in sickle cell anaemia.
Topics: alpha-Thalassemia; Anemia, Sickle Cell; Antisickling Agents; Female; Fetal Hemoglobin; Genetic Predi | 2005 |
New therapies for sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Calcium Channel Blockers; Cell Adhesion; Fatty Acids, Omega-3; Huma | 2005 |
The pathophysiology, prevention, and treatment of stroke in sickle cell disease.
Topics: Anemia, Sickle Cell; Blood Transfusion; Humans; Hydroxyurea; Stroke; Ultrasonography, Doppler, Trans | 2007 |
Hematopoietic cell transplantation: a curative option for sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Child, Preschool; Female; Hemato | 2007 |
Management of cerebral vasculopathy in children with sickle cell anaemia.
Topics: Adolescent; Adult; Algorithms; Antisickling Agents; Blood Transfusion; Bone Marrow Transplantation; | 2000 |
[What vascular events suggest a myeloproliferative disorder?].
Topics: Adult; Aged; Alkylating Agents; Arterial Occlusive Diseases; Cross-Sectional Studies; Erythromelalgi | 2000 |
Stroke prevention and treatment in sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Bone Marrow Transplantation; Humans; Hy | 2001 |
Acute complications of sickle cell disease in children.
Topics: Abdominal Pain; Acute Disease; Adolescent; Analgesics; Anemia, Aplastic; Anemia, Sickle Cell; Animal | 2001 |
33 trials available for hydroxyurea and Apoplexy
Article | Year |
---|---|
Economic evaluation of regular transfusions for cerebral infarct recurrence in the Silent Cerebral Infarct Transfusion Trial.
Topics: Blood Transfusion; Cerebral Infarction; Child; Cost-Benefit Analysis; Humans; Hydroxyurea; Stroke; U | 2021 |
Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Method; Female; Humans; Hyd | 2022 |
Translating research to usual care of children with sickle cell disease in Northern Nigeria: lessons learned from the SPRING Trial Team.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Nigeria; Stroke; Ultrasonography, Dop | 2022 |
Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa.
Topics: Adolescent; Africa South of the Sahara; Anemia, Sickle Cell; Child; Child, Preschool; Female; Humans | 2023 |
PRIMARY STROKE PREVENTION IN CHILDREN WITH SICKLE CELL ANEMIA LIVING IN AFRICA: THE FALSE CHOICE BETWEEN PATIENT-ORIENTED RESEARCH AND HUMANITARIAN SERVICE-PART II.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Nigeria; Stroke | 2022 |
Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Nigeria; Secondary Prevention; | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial.
Topics: Adolescent; Adult; Africa; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Stroke; Zinc | 2023 |
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Stroke; Tanzania | 2023 |
Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Donors; Blood Safety; Blood Transfusion; Chelation The | 2020 |
Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.
Topics: Anemia, Sickle Cell; Child; Child, Preschool; Female; Humans; Hydroxyurea; Male; Nigeria; Stroke | 2020 |
Establishing Sickle Cell Disease Stroke Prevention Teams in Africa is Feasible: Program Evaluation Using the RE-AIM Framework.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Humans; Hydroxyurea; Male | 2022 |
What drives transcranial Doppler velocity improvement in paediatric sickle cell anaemia: analysis from the Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort study.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Child; Child, Preschool; Female; Hemo | 2021 |
Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Cerebrovascular Circulati | 2021 |
Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Studies; Hospit | 2017 |
Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa.
Topics: Africa South of the Sahara; alpha-Thalassemia; Anemia, Sickle Cell; Blood Transfusion; Child; Child, | 2018 |
Building capacity to reduce stroke in children with sickle cell anemia in the Dominican Republic: the SACRED trial.
Topics: Anemia, Sickle Cell; Antisickling Agents; Capacity Building; Child; Dominican Republic; Humans; Hydr | 2018 |
Hydroxyurea reduces cerebral metabolic stress in patients with sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Cerebrovascular Circulation; Child; Female; Humans; Hydroxyu | 2019 |
Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Stu | 2019 |
Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Stu | 2019 |
Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Stu | 2019 |
Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Stu | 2019 |
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
Topics: Acute Chest Syndrome; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Chelat | 2013 |
Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial.
Topics: Adolescent; Anemia, Sickle Cell; Blood Flow Velocity; Blood Transfusion; Brain; Cerebrovascular Circ | 2014 |
Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Feasibility Studies; Female; Foll | 2015 |
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Biological Assay; Child; Child, Pre | 2015 |
Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Female; Ferritins; Humans; Hydroxyurea; Iron; Iron | 2016 |
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Blood Transfusion; Cerebr | 2016 |
Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities.
Topics: Anemia, Sickle Cell; Blood Flow Velocity; Blood Transfusion; Cerebrovascular Circulation; Female; Fo | 2016 |
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.
Topics: Adolescent; Adult; Anemia, Sickle Cell; DNA Damage; Drug Utilization; Early Termination of Clinical | 2010 |
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Chelation Therapy; Child; Child, Preschool; Erythrocyte Tran | 2011 |
Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities.
Topics: Anemia, Sickle Cell; Autoantibodies; Blood Flow Velocity; Cerebrovascular Circulation; Child; Child, | 2012 |
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Maxi | 2012 |
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Maxi | 2012 |
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Maxi | 2012 |
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Maxi | 2012 |
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Body Height; Body Weight; C | 2005 |
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Body Height; Body Weight; C | 2005 |
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Body Height; Body Weight; C | 2005 |
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Body Height; Body Weight; C | 2005 |
Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Blood Transfusion; Child; Child, Pres | 2007 |
Limitations of clinical trials in sickle cell disease: a case study of the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Multicenter Studies as Topic; Randomized Controlled Trials | 2007 |
57 other studies available for hydroxyurea and Apoplexy
Article | Year |
---|---|
Neurocognitive functioning in children with sickle cell anemia and history of abnormal transcranial doppler ultrasonography.
Topics: Adolescent; Anemia, Sickle Cell; Blood Flow Velocity; Blood Transfusion; Child; Female; Humans; Hydr | 2022 |
Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Humans; Hydroxyurea; Midd | 2023 |
Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Child; Child, Preschool; Cross-Sectional Studies | 2023 |
Hydroxyurea: how much is enough?
Topics: Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Nigeria; Secondary Prevention; Stroke | 2023 |
Hydroxyurea and stroke prevention in sickle cell anaemia: the challenge of application in sub-Saharan Africa.
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Stroke | 2023 |
Changes in Hydroxyurea Use Among Youths Enrolled in Medicaid With Sickle Cell Anemia After 2014 Revision of Clinical Guidelines.
Topics: Adolescent; Anemia, Sickle Cell; Cross-Sectional Studies; Humans; Hydroxyurea; Male; Medicaid; Strok | 2023 |
[A case of recurrent non embolic stroke with non-fluent aphasia due to polycythemia vera].
Topics: Aged; Aphasia; Cerebral Infarction; Female; Humans; Hydroxyurea; Polycythemia Vera; Stroke | 2023 |
Enhanced brain delivery of hypoxia-sensitive liposomes by hydroxyurea for rescue therapy of hyperacute ischemic stroke.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Ischemia; Endothelial Cells; Hydroxyurea; Hypoxia; Ischem | 2023 |
Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Humans; Hydroxyurea; Infa | 2019 |
Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Hematocrit; H | 2020 |
Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort.
Topics: Anemia, Sickle Cell; Blood Flow Velocity; Humans; Hydroxyurea; Stroke; Uganda; Ultrasonography, Dopp | 2020 |
Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Donors; Blood Safety; Blood Transfusion; Child; Chil | 2020 |
American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.
Topics: Adult; Anemia, Sickle Cell; Child; Hematology; Hemoglobin, Sickle; Humans; Hydroxyurea; Stroke; Unit | 2020 |
COVID-19 and SCA: an old friend comes to the rescue.
Topics: Betacoronavirus; Child; Coronavirus Infections; COVID-19; Friends; Humans; Hydroxyurea; Pandemics; P | 2020 |
Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10-year longitudinal study on the SPPIBA cohort.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Humans; Hydro | 2021 |
Chronic organ injuries in children with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Humans; Hydroxyurea; Stroke | 2021 |
Transverse melanonychia and palmar hyperpigmentation secondary to hydroxyurea therapy.
Topics: Aged, 80 and over; Antineoplastic Agents; Diagnosis, Differential; Female; Hand; Humans; Hydroxyurea | 2017 |
Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Cerebrovascular Circulati | 2019 |
Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms.
Topics: Humans; Hydroxyurea; Leukocyte Count; Myeloid Cells; Myeloproliferative Disorders; Recurrence; Strok | 2018 |
Hydroxyurea for Primary Stroke Prevention: The time draweth nigh.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Incidence; Nigeria; Stroke | 2019 |
Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease.
Topics: Anemia, Sickle Cell; Child; Clinical Trials as Topic; Cognitive Dysfunction; Endpoint Determination; | 2019 |
Current management of sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Clinical Trials as Topic; Early Diagnosis; Evidence | 2013 |
Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
Topics: Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Cerebral Infarction; Cerebr | 2013 |
Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Disabled Children; Female; Humans | 2013 |
Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis.
Topics: Female; Humans; Hydroxyurea; Hyperpigmentation; Middle Aged; Nail Diseases; Nails; Stroke; Thrombocy | 2014 |
Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers.
Topics: Acute Chest Syndrome; Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; | 2014 |
[Hydroxyurea-induced pneumonia].
Topics: Aged; Antineoplastic Agents; Female; Humans; Hydroxyurea; Lymphoproliferative Disorders; Pneumonia; | 2014 |
Primary stroke in a woman with sickle cell anemia responsive to hydroxyurea therapy.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Brain Ischemia; Echocardiography, Transesophageal; | 2014 |
Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.
Topics: Adolescent; Anemia, Sickle Cell; Blood Cell Count; Blood Flow Velocity; Blood Transfusion; Cerebral | 2015 |
Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Cost-Benefit Analysis; Developing Countries; Female | 2015 |
Hydroxyurea for abnormal TCDs: safe to switch?
Topics: Anemia, Sickle Cell; Blood Transfusion; Cerebrovascular Circulation; Female; Humans; Hydroxyurea; Ma | 2016 |
Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: impact of national guidelines.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Child; Child, Preschool; Cohort Studies; Female; Follow-U | 2016 |
Venous sinus thrombosis leading to stroke in a patient with sickle cell disease on hydroxyurea and high hemoglobin levels: treatment with thrombolysis.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Brain Infarction; Dura Mater; Follow-Up Studies; He | 2008 |
The clinical care of adult patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Female; Genetic Testing; Heart Diseases; Humans; Hy | 2008 |
Hydroxyurea or chronic exchange transfusions in patients with sickle cell disease: role of transcranial Doppler ultrasound in stroke prophylaxis.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Cerebral Arteries; Cerebrovascular Ci | 2009 |
Essential thrombocythemia transforming into acute biphenotypic leukemia in a patient on hydroxyurea monotherapy.
Topics: Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Female; Humans; Hydroxyurea; Leukemia, | 2009 |
Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Cohort Studies; Combined Modalit | 2011 |
Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management.
Topics: Adolescent; Africa; Anemia, Sickle Cell; Antisickling Agents; Belgium; Bone Marrow Transplantation; | 2010 |
Is it time to SWiTCH to composite primary endpoints?
Topics: Anemia, Sickle Cell; Erythrocyte Transfusion; Humans; Hydroxyurea; Iron Overload; Stroke | 2011 |
Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke.
Topics: Anemia, Sickle Cell; Child; Cohort Studies; Female; Humans; Hydroxyurea; Male; Recurrence; Stroke | 2011 |
Limitations of Hb F as a phenotypic modifier in sickle cell disease: study of Kuwaiti Arab patients.
Topics: alpha-Thalassemia; Anemia, Sickle Cell; Arabs; Femur Head Necrosis; Fetal Hemoglobin; Genetic Associ | 2011 |
Bilateral vertebral artery dissection and essential thrombocythemia with JAK2 mutation.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Brain Ischemia; Diplopia; Female; Humans; Hydroxyurea; | 2012 |
Decades after the cooperative study: a re-examination of systemic blood pressure in sickle cell disease.
Topics: Adolescent; Adult; Age Distribution; Aged; Anemia, Sickle Cell; Bilirubin; Blood Pressure; Body Mass | 2012 |
Repeated episodes of ischemic stroke over a short period in a patient with essential thrombocythemia on anticoagulant therapy.
Topics: Aged; Anticoagulants; Aphasia; Brain Ischemia; Cerebral Angiography; Cilostazol; Diffusion Magnetic | 2014 |
Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
Topics: Adolescent; Adult; Age Factors; Anemia, Sickle Cell; Blood Transfusion; Chelation Therapy; Child; Ch | 2013 |
Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Fetal Hemoglo | 2002 |
Expanding the role of hydroxyurea in children with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Stroke; Transfusion Reaction; | 2004 |
Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Humans; Hydro | 2004 |
Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Belgium; Child; Child, Preschool; Femal | 2005 |
Hydroxyurea as secondary prevention for stroke in children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Incidence; Secondary Preventio | 2005 |
[The diagnosis and treatment of polycythemia rubra vera manifesting as acute cerebral stroke].
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Female; Harringtonines; Hemato | 2006 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Steroid treatment in children with sickle-cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Arthritis; Autoimmune Diseases; Blood Transfusion; Child; Child, Pr | 2007 |
Use of hydroxyurea in prevention of stroke in children with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Blood Transfusion; Child; Child, Pres | 2008 |
Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion | 1999 |
Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2000 |
Five years of experience with hydroxyurea in children and young adults with sickle cell disease.
Topics: Acute Disease; Adolescent; Adult; Anemia, Aplastic; Anemia, Sickle Cell; Antisickling Agents; Arteri | 2001 |